<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; bharat</title>
	<atom:link href="http://www.tapanray.in/tag/bharat/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pills and Payments: India&#8217;s Unethical Drug Marketing Problem</title>
		<link>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pills-and-payments-indias-unethical-drug-marketing-problem</link>
		<comments>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/#comments</comments>
		<pubDate>Fri, 27 Jun 2025 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10925</guid>
		<description><![CDATA[The recent exposé by The Economic Times, titled &#8220;Rx Name Unethical practitioners,&#8221; published on June 19, 2025, which brought to light allegations of a prominent global pharmaceutical company sponsoring extravagant foreign trips for doctors in violation of ethical codes, serves as &#8230; <a href="http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Curbing Patent Evergreening: Advancing Innovation and Health Equity for a Vikshit Bharat</title>
		<link>http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat</link>
		<comments>http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/#comments</comments>
		<pubDate>Sat, 03 May 2025 07:43:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents Act]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Secondary patents]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10892</guid>
		<description><![CDATA[As published in The Economic Times of April 27, 2025:  India’s Commerce and industry minister - “Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as &#8216;evergreening,&#8217; for prioritizing corporate profits over &#8230; <a href="http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MAGA vs. Viksit Bharat: Trump&#8217;s Tariffs And India&#8217;s Pharma Dreams</title>
		<link>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams</link>
		<comments>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/#comments</comments>
		<pubDate>Tue, 15 Apr 2025 08:32:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[dreams]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MAGA]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reciprocal]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10888</guid>
		<description><![CDATA[A high-stakes clash poses a potential threat to PM Modi&#8217;s &#8216;Viksit Bharat&#8217; Vision, exposing India&#8217;s pharmaceutical vulnerability and forcing a strategic reckoning. The resurgence of Donald Trump&#8217;s &#8220;America First&#8221; MAGA (Make America Great Again) agenda casts a long, ominous shadow &#8230; <a href="http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deadly Climate Change Impact On Human Health: How Prepared Is India?</title>
		<link>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deadly-climate-change-impact-on-human-health-how-prepared-is-india</link>
		<comments>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/#comments</comments>
		<pubDate>Mon, 12 Aug 2019 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Ayushman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change. global]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[gainers]]></category>
		<category><![CDATA[greenhouse]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Paris]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researching]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[warming]]></category>
		<category><![CDATA[Zika]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9665</guid>
		<description><![CDATA[It’s not uncommon to find many people, including heads of countries, expressing their serious apprehensions in public, about the scary impact of climate change. Just the last year, on November 26, 2018, BBC News captured one of such incidences with the astonishing &#8230; <a href="http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will AB-NHPM Mitigate Indian Healthcare Crisis?</title>
		<link>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-ab-nhpm-mitigate-indian-healthcare-crisis</link>
		<comments>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/#comments</comments>
		<pubDate>Mon, 18 Jun 2018 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Ayusman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inpatient]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHFS]]></category>
		<category><![CDATA[NHM]]></category>
		<category><![CDATA[NHPM]]></category>
		<category><![CDATA[NHRM]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outpatient]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RSBY]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tertiary]]></category>
		<category><![CDATA[transportation]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9039</guid>
		<description><![CDATA[Since long, hypes have created on several healthcare schemes in India, by the successive Governments of different political dispensation. These attracted mostly positive vibes at the time of announcements. Nevertheless, as we move on, a vast majority of Indians continues &#8230; <a href="http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
